EQS-News

AATec to Present Data from Lead Candidate ATL-105 at World Bronchiectasis Conference 2026 18.06.2026, 09:30 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: AATec Medical GmbH / Key word(s): Conference
AATec to Present Data from Lead Candidate ATL-105 at World Bronchiectasis Conference 2026

18.06.2026 / 09:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


AATec to Present Data from Lead Candidate ATL-105 at World Bronchiectasis Conference 2026

  • Preclinical data demonstrate ATL-105’s multimodal effects for the treatment of non-CF bronchiectasis, including broad activity against key disease drivers such as neutrophil serine proteases, inflammatory mediators and infections
  • Phase 1/2 proof-of-concept trial in non-CF bronchiectasis is in preparation, with study start planned for 2026

Munich, Germany, June 17, 2026 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform for the treatment of respiratory diseases, today announced that it will present preclinical data for its lead candidate ATL-105 at the 9th World Bronchiectasis Conference, taking place from 24 to 27 June 2026 in Hannover, Germany. The poster will highlight key results for ATL-105, AATec’s new recombinant version of alpha-1 antitrypsin (AAT) with optimized properties as an inhaled treatment candidate for non-cystic fibrosis bronchiectasis (non-CF bronchiectasis, NCFB).

The poster, titled “ATL-105, a novel multimodal serine protease inhibitor with immunomodulatory and anti-infective properties for the treatment of non-CF bronchiectasis,” will present preclinical data showing that ATL-105 broadly inhibits neutrophil serine proteases with high activity, modulates inflammatory responses, reduces bacterial virulence factors and targets factors involved in viral disease exacerbations. The poster also reports data of ATL-105 in representative in vivo models of lung inflammation.

In addition, data will be presented demonstrating the effective nebulization of ATL-105 for inhaled delivery, with high stability during aerosolization and efficient deposition in disease-relevant regions of the airways.

“These preclinical findings further support ATL-105’s multimodal profile in non-CF bronchiectasis,” commented Dr. Gabriele Matschiner, Chief Development Officer of AATec Medical GmbH. “The data show activity across key disease drivers, while also supporting the product candidate’s suitability for inhaled delivery. Together, these results reinforce the strong rationale for clinical development of ATL-105 in this indication.”

“Non-CF bronchiectasis is a complex disease marked by chronic inflammation, progressive lung damage and recurrent infection that affects over three million patients in Western countries alone,” said Dr. Rüdiger Jankowsky, Chief Executive Officer of AATec Medical GmbH. “ATL-105 offers a differentiated inhaled treatment approach by broadly addressing multiple disease drivers that contribute to the progression of NCFB. With our Phase 1/2 proof-of-concept trial in preparation, we are working to start clinical development of ATL-105 later this year.”

The start of the Phase 1/2 proof-of-concept trial of ATL-105 in patients with non-CF bronchiectasis is planned for 2026 and the development strategy has been aligned with EU and US regulators.

About AATec

AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-of-concept clinical trial with its lead product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec is operated by a seasoned interdisciplinary expert team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit https://www.aatec-medical.com/ and follow us on LinkedIn.

Contact
AATec Medical GmbH
Dr. Rüdiger Jankowsky, CEO
Email: info@aatec-medical.com

Media Contact
MC Services
Katja Arnold, Julia von Hummel
Email: aatec-medical@mc-services.eu
Phone: +49 (0)89 2102280



18.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: AATec Medical GmbH
Brunnengasse 27
85662 Hohenbrunn
Germany
E-mail: ruediger.jankowsky@aatec-medical.com
Internet: https://aatec-medical.com/
EQS News ID: 2348612

 
End of News EQS News Service

2348612  18.06.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 21:05 Uhr • Artikel • dpa-AFX

Gestern 20:35 Uhr • Artikel • dpa-AFX

Gestern 20:34 Uhr • Artikel • dpa-AFX

Gestern 20:33 Uhr • Artikel • dpa-AFX

Gestern 20:32 Uhr • Artikel • dpa-AFX

Gestern 20:29 Uhr • Artikel • dpa-AFX

Gestern 20:28 Uhr • Artikel • dpa-AFX

Gestern 20:27 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer